P. Jansen

发表

Role of ‘‘mass balance’’ in pharmaceutical stress testing

S. Baertschi, M. Nussbaum, A. Kaerner, 2005 .

Determination of relative UV response factors for HPLC by use of a chemiluminescent nitrogen-specific detector.

S. Baertschi, M. Nussbaum, P. Jansen, 2002, Journal of pharmaceutical and biomedical analysis.

Artifacts Generated During Azoalkane Peroxy Radical Oxidative Stress Testing of Pharmaceuticals Containing Primary and Secondary Amines.

P. Harmon, S. Baertschi, Todd Zelesky, 2015, Journal of pharmaceutical sciences.

Implications of in-use photostability: proposed guidance for photostability testing and labeling to support the administration of photosensitive pharmaceutical products, part 1: drug products administered by injection.

Steven W Baertschi, Robert A Reed, D. Clapham, 2013, Journal of pharmaceutical sciences.

Investigation of the mechanism of racemization of litronesib in aqueous solution: unexpected base-catalyzed inversion of a fully substituted carbon chiral center.

Michael A. Watkins, G. Stephenson, T. Harris, 2014, Journal of pharmaceutical sciences.

Stress testing: Analytical considerations

S. Baertschi, P. Jansen, W. K. Smith, 2016 .

Assessing the Relevance of Solution Phase Stress Testing of Solid Dosage Form Drug Products: A Cross-Industry Benchmarking Study.

S. Baertschi, L. Allain, Chloe Q. Wang, 2021, Journal of pharmaceutical sciences.

Recent Trends in Product Development and Regulatory Issues on Impurities in Active Pharmaceutical Ingredient (API) and Drug Products. Part 2: Safety Considerations of Impurities in Pharmaceutical Products and Surveying the Impurity Landscape

Karen M. Alsante, G. Stephenson, R. Reed, 2013, AAPS PharmSciTech.

Characterization of impurities formed by interaction of duloxetine HCl with enteric polymers hydroxypropyl methylcellulose acetate succinate and hydroxypropyl methylcellulose phthalate.

S. Baertschi, S. Maple, P. Jansen, 1998, Journal of pharmaceutical sciences.

Recent Trends in Product Development and Regulatory Issues on Impurities in Active Pharmaceutical Ingredient (API) and Drug Products. Part 2: Safety Considerations of Impurities in Pharmaceutical Products and Surveying the Impurity Landscape

Karen M. Alsante, Margaret S. Landis, G. Stephenson, 2014, AAPS PharmSciTech.

The Degradation Chemistry of Prasugrel Hydrochloride: Part 1-Drug Substance.

K. W. Taylor, S. Baertschi, A. Kaerner, 2019, Journal of pharmaceutical sciences.

Packaging-Induced Interactions and Degradation

P. Jansen, M. Argentine, 2010 .

Stress Testing: A Predictive Tool

Karen M. Alsante, S. Baertschi, P. Jansen, 2016 .

The degradation of the antitumor agent gemcitabine hydrochloride in an acidic aqueous solution at pH 3.2 and identification of degradation products.

S. Baertschi, S. Maple, M. Akers, 2000, Journal of pharmaceutical sciences.

Isolation, identification, and synthesis of two oxidative degradation products of olanzapine (LY170053) in solid oral formulations.

H. Brunner, S. Baertschi, S. Maple, 2008, Journal of pharmaceutical sciences.

Formation of copper(I) from trace levels of copper(II) as an artifactual impurity in the HPLC analysis of olanzapine.

N. Toltl, S. Baertschi, B. Olsen, 2016, Journal of Pharmaceutical and Biomedical Analysis.